Neurostimulation and neurosensing techniques to optimize atrial anti-tachycardia pacing for termination of atrial tachyarrhythmias

• US 7,826,899 B1
• Filed: 12/22/2006
• Issued: 11/02/2010
• Est. Priority Date: 12/22/2006
• Status: Expired due to Fees

• Current Assignee: Pacesetter Incorporated (Abbott Laboratories Incorporated)
• Original Assignee: Pacesetter Incorporated (Abbott Laboratories Incorporated)
• Inventors: Gill, Jong, Ryu, Kyungmoo, Bornzin, Gene A., Farazi, Taraneh Ghaffari
• Primary Examiner(s): Evanisko; George R
• Assistant Examiner(s): HAYES, ANDREW L
• Application Number:
  US11/615,488
• Time in Patent Office: 1,411 Days
• Field of Search: 607/14, 607/15, 607/17, 607/18
• US Class Current: 607/14
• CPC Class Codes: A61N 1/36114 Cardiac control, e.g. by vagal stimulation stimulating the heart A61N1/362
• CPC Class Codes: A61N 1/3621 for treating or preventing abnormally high heart rate
• CPC Class Codes: A61N 1/3624 occurring in the atrium, i.e. atrial tachycardia

Abstract

Implantable systems, and method for use therewith, are provided that take advantage of various neuromodulation and neurosensing techniques for either preventing atrial fibrillation (AF) or terminating AF. Specific embodiments, as will be described below, are for use with an implantable device that include one or more atrial electrode for sensing atrial fibrillation (AF) and/or delivering AATP and one or more electrode for monitoring and/or stimulating atrial vagal fat pads.

Claims

1. In an implantable system that includes a plurality of atrial electrodes for one or both of sensing atrial fibrillation (AF) and delivering atrial antitachycardia pacing (AATP) and a plurality of electrodes for one or both of monitoring and stimulating atrial vagal fat pads, a method for terminating AF, the method comprising:

(a) monitoring at least one of the atrial electrodes for AF;

(b) monitoring at least two of the atrial vagal fat pads for hyperactivity; and

(c) in response to detecting AF and detecting at least two hyperactive atrial vagal fat pads

(c.1) selecting, for delivering AATP, the atrial electrode that is closest to the hyperactive atrial vagal pad that is selected from the group consisting of

the hyperactive atrial vagal fat pad having a longest duration of hyperactivity,

the hyperactive atrial vagal fat pad having a most intense action potential, and

the hyperactive atrial vagal fat pad with a most irregular hyperactivity;

(c.2) stimulating at least one of the atrial vagal fat pads; and

(c.3) delivering AATP using the atrial electrode selected at step (c.1), to thereby terminate AF.

2. The method of claim 1, wherein step (c.1) comprises selecting, for delivering AATP, the atrial electrode that is closest to the hyperactive atrial vagal fat pad having a longest duration of hyperactivity.

3. The method of claim 1, wherein step (c.1) comprises selecting, for delivering AATP, the atrial electrode that is closest to the hyperactive atrial vagal fat pad having a most intense action potential.

4. The method of claim 1, wherein step (c.1) comprises selecting, for delivering AATP, the atrial electrode that is closest to the hyperactive atrial vagal fat pad with a most irregular hyperactivity.

5. The method of claim 1, wherein one or more intrapericardial electrodes implanted through a subxiphoid approach are used to monitor for one or both of AF and hyperactivity.

9. The method of claim 1, wherein the implantable system, including all of the electrodes, is chronically implanted.

12. The method of claim 1, wherein said stimulating at least one of the atrial vagal fat pads coincides approximately in time with said delivering AATP.

13. The method of claim 1, wherein said stimulating at least one of the atrial vagal fat pads precedes in time said delivering AATP.

14. The method of claim 1, wherein said stimulating at least one of the atrial vagal fat pads is approximately synchronous in time with said delivering AATP.

15. The method of claim 1, wherein said stimulating at least one of the atrial vagal fat pads triggers said delivering AATP.

16. The method of claim 1, wherein said stimulating at least one of the atrial vagal fat pads comprises stimulating two or more atrial vagal fat pads approximately simultaneously in time.

17. The method of claim 1, wherein said stimulating at least one of the atrial vagal fat pads comprises stimulating two or more atrial vagal fat pads sequentially.

6. An implantable system, comprising:

a plurality of atrial electrodes for one or both of sensing atrial fibrillation (AF) and delivering atrial antitachycardia pacing (AATP);

a plurality of electrodes for one or both of monitoring and stimulating atrial vagal fat pads;

an AF monitor to monitor at least one of the atrial electrodes for AF;

a vagal fat pad monitor to monitor at least one of the atrial vagal fat pads for hyperactivity; and

a selector to select at least one of the atrial electrodes for delivering atrial anti-tachycardia pacing (AATP), in response to detecting AF, based on an output of the vagal fat pad monitor;

a vagal fat pad stimulation controller to stimulate at least one of the atrial vagal fat pads, in response to detecting AF; and

an AATP controller to deliver AATP using the selected at least one of the atrial electrodes, to thereby terminate AF;

wherein when the AF monitor detects AF and the vagal fad pad monitor detects at least two hyperactive atrial vagal fat pads, the AATP controller selects, for delivering AATP, the atrial electrode that is closest to the hyperactive atrial vagal pad that is selected from the group consisting of

the hyperactive atrial vagal fat pad having a longest duration of hyperactivity,

the hyperactive atrial vagal fat pad having a most intense action potential, and

the hyperactive atrial vagal fat pad with a most irregular hyperactivity.

10. The implantable system of claim 6, wherein the implantable system, including the atrial electrodes, the electrodes for one or both of monitoring and stimulating atrial vagal fat pads, the AF monitor, the vagal fat pad monitor, the selector, the vagal fat pad stimulation controller and the AATP controller, is chronically implantable.

7. A method for terminating atrial fibrillation (AF) comprising:

(a) monitoring for AF using atrial electrodes;

(b) monitoring atrial vagal fat pads for hyperactivity; and

(c) in response to detecting AF and detecting at least two hyperactive atrial vagal fat pads

(c.1) selecting, for delivering atrial anti-tachycardia pacing (AATP), the atrial electrode that is closest to the hyperactive atrial vagal pad that is selected from the group consisting of

the hyperactive atrial vagal fat pad having a longest duration of hyperactivity,

the hyperactive atrial vagal fat pad having a most intense action potential, and

the hyperactive atrial vagal fat pad with a most irregular hyperactivity;

(c.2) stimulating at least one of the atrial vagal fat pads; and

(c.3) delivering AATP using the atrial electrode selected at step (c.1), to thereby terminate AF.

8. The method of claim 7, wherein:

step (c.2) comprises stimulating only one atrial vagal fat pad at a time; and

step (c.1) comprises also selecting, for delivering AATP, the atrial electrode that is closest to the stimulated atrial vagal fat pad.

11. The method of claim 7, wherein the method is performed by a chronically implanted system that includes the atrial electrodes and includes electrodes used for stimulating at least one of the atrial vagal fat pads.